Dr. Altschuler's laboratory studies mechanisms of signal transduction by the second messenger cAMP in cell proliferation. cAMP-dependent protein kinase (PKA) and Exchange protein activated by cAMP (Epac) represent the main effectors of cAMP action. Both pathways converge at the level of the small GTPase Rap1b, via its Epac-mediated activation and PKA-mediated phosphorylation. The role of Rap1 activation (Epac) and phosphorylation (PKA) coordinating the early rate-limiting events in cAMP-dependent cell proliferation are studied using a multidisciplinary approach including molecular and cellular biology techniques in vitro, as well as in vivo validation using transgenic/knock in technologies in endocrine tumor models.
Dr. Edward Chu is involved in basic, clinical, and translational cancer research. His basic research interests are focused on the characterization of molecular mechanisms underlying the development of cellular drug resistance, especially as it relates to the fluoropyrimidine class of anticancer agents. His research group was the first to identify translational autoregulation as a novel regulatory mechanism in eukaryotes for controlling the expression of the folate-dependent enzymes, thymidylate synthase and dihydrofolate reductase. His clinical/translational research efforts focus on identifying novel drugs and treatment strategies for colorectal cancer and other GI cancers and in developing early phase clinical trials. He has a strong interest in integrating Chinese herbal medicine with standard cancer chemotherapy, with the goal of enhancing clinical activity and reducing toxicities.
Our research is directed toward developing fundamentally new transformations and highlighting their utility for complex molecule synthesis.
The research in the Intini Lab focuses on skeletal stem cells and of bone cancer stem cells. Genetic strategies and in vivo imaging are utilized to describe the location and function of these cells and the molecular mechanisms that control their "stemness” in health and disease.